|Bid||151.93 x 800|
|Ask||182.50 x 800|
|Day's Range||164.71 - 168.89|
|52 Week Range||86.88 - 178.64|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||39.28|
|Earnings Date||May 03, 2021 - May 07, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||200.82|
The biggest news for Jazz Pharmaceuticals (NASDAQ: JAZZ) in recent months was the company's announcement earlier this month that it plans to acquire GW Pharmaceuticals in a $7.6 billion deal. Now, Jazz has more news that investors eagerly awaited. Here are the highlights from Jazz's Q4 update.
JAZZ earnings call for the period ending December 31, 2020.
Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 9.50% year over year to $4.00, which missed the estimate of $4.20. Revenue of $665,517,000 higher by 14.40% year over year, which beat the estimate of $639,550,000. Outlook Jazz Pharma Sees FY21 Sales $2.55B-$2.7B vs $2.56B Estimate, Adj. EPS $15.65-$16.85 vs $16.78 Estimate Conference Call Details Date: Feb 23, 2021 Time: 04:30 PM View more earnings on JAZZ ET Webcast URL: https://edge.media-server.com/mmc/p/7h5iem3y Price Action 52-week high: $172.67 Company's 52-week low was at $86.88 Price action over last quarter: Up 5.93% Company Description Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021Preview: Jazz Pharmaceuticals's Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.